Floatz logo

Posaconazole

Fungal Infectious Disease

Bochud Pierre-YvesSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Fungal Infectious Disease cohort.

Asset / SponsorPhaseRating
Caspofungin
Texas Tech University Health Sciences Center
Phase 4BBB
Anidulafungin
Texas Tech University Health Sciences Center
Phase 4BB
SUBA-ITRACONAZOLE COMPONENT ITRACONAZOLE
Samsung Medical Center
Phase 4BB
Fluconazole
Bochud Pierre-Yves
Phase 3BB
L-Ofloxacin
Children's Oncology Group
Phase 3BB
Voriconazole
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3B
Cyclosporin A
Stanford University
Phase 2B
ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN, RABBIT
Stanford University
Phase 2B

Same molecule, other indications

Posaconazole is also rated in:

acute myeloid leukemiaActive
BBB
Indicative · Phase 4
74 / 100
View asset →
neutropeniaDormant
BB
Indicative · Phase 4
67 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →